Corcept Therapeutics | CORT - Current Assets


Corcept Therapeutics reported $439.68M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
ANI Pharmaceuticals USD 825.43M 78.35M Jun/2026
Ardelyx USD 381.87M 447K Mar/2026
Aurora Cannabis CAD 397.45M 48.38M Mar/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
J&J USD 59.77B 601M Jun/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Merck USD 36.68B 1.66B Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 615.21M 100.25M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026